{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.4019",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Clinical Architecture"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2023-06-21"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2020-12-17"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4019",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4019"
    }
  ],
  "version" : "20201217",
  "name" : "COVID19ICD10PCSValueSetForAdministrationOfTocilizumab",
  "title" : "COVID19 ICD10PCS Value Set for Administration of Tocilizumab",
  "status" : "retired",
  "experimental" : false,
  "date" : "2023-06-21T18:16:37-04:00",
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to administration of tocilizumab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of tocilizumab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other interleukin-6 antagonists (e.g., sarilumab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "concept" : [
          {
            "code" : "XW033H5",
            "display" : "Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"
          },
          {
            "code" : "XW043H5",
            "display" : "Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:f6fb2fcc-1080-4803-b3a5-be843687d823",
    "timestamp" : "2024-06-14T16:16:48-04:00",
    "total" : 2,
    "contains" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2024",
        "code" : "XW033H5",
        "display" : "Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2024",
        "code" : "XW043H5",
        "display" : "Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"
      }
    ]
  }
}
